Arno Therapeutics 10-Q 16 May 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 11, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	Arno Therapeutics, Inc
Entity Central Index Key	1,195,116
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ARNI
Entity Common Stock, Shares Outstanding		41,562,613

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 2,683,940	$ 66,988
Prepaid expenses and other current assets	208,644	260,694
Total current assets	2,892,584	327,682
Property and equipment, net	21,322	23,103
Security deposit	10,455	10,455
Total assets	2,924,361	361,240
Current liabilities
Accounts payable	787,881	1,010,215
Accrued expenses and other current liabilities	502,008	1,124,690
Convertible notes, net of financing costs of $10,091 at December 31, 2015	0	2,089,909
Capital lease obligation- short term	3,998	3,853
Deferred rent	2,084	1,910
Total current liabilities	1,295,971	4,230,577
Capital lease obligation- long term	3,014	4,070
Derivative liabilities	5,648,582	4,750,687
Total liabilities	$ 6,947,567	$ 8,985,334
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 35,000,000 shares authorized, none issued and outstanding	$ 0	$ 0
Common stock, $0.0001 par value, 500,000,000 shares authorized, 41,562,613 and 20,408,616 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	7,584	5,469
Additional paid-in capital	92,973,110	84,665,390
Accumulated deficit	(97,003,900)	(93,294,953)
Total stockholders' deficit	(4,023,206)	(8,624,094)
Total liabilities and stockholders' deficit	$ 2,924,361	$ 361,240

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Unamortized Debt Issuance Expense		$ 10,091
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	35,000,000	35,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	41,562,613	20,408,616
Common stock, shares outstanding	41,562,613	20,408,616

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating expenses:
Research and development	$ 1,544,338	$ 2,474,869
General and administrative	1,280,948	1,387,615
Total operating expenses	2,825,286	3,862,484
Loss from operations	(2,825,286)	(3,862,484)
Other income/(expense):
Interest income	2,039	4,522
Interest expense	(14,518)	(410)
Other income/(expense), net	(871,182)	469,581
Total other income/(expense)	(883,661)	473,693
Net loss	$ (3,708,947)	$ (3,388,791)
Net loss per share - basic & diluted	$ (0.10)	$ (0.17)
Weighted-average shares outstanding- basic & diluted	38,773,075	20,408,616

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - 3 months ended Mar. 31, 2016 - USD ($)	Total	PREFERRED STOCK	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT
Balance at Dec. 31, 2015	$ (8,624,094)	$ 0	$ 5,469	$ 84,665,390	$ (93,294,953)
Balance (in shares) at Dec. 31, 2015		0	20,408,616
Issuance of common shares upon conversion of note payable and accrued interest	2,128,652		$ 608	2,128,044
Issuance of common shares upon conversion of note payable and accrued interest (in shares)			6,081,858
Issuance of common shares pursuant to a stock purchase agreement, net of issuance costs of $2,500	5,272,750		$ 1,507	5,271,243
Issuance of common shares pursuant to a stock purchase agreement, net of issuance costs of $2,500 (in shares)			15,072,139
Net loss	(3,708,947)	$ 0	$ 0	0	(3,708,947)
Stock based compensation for services	908,433	0	0	908,433	0
Balance at Mar. 31, 2016	$ (4,023,206)	$ 0	$ 7,584	$ 92,973,110	$ (97,003,900)
Balance (in shares) at Mar. 31, 2016		0	41,562,613

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parenthetical)	3 Months Ended
	Mar. 31, 2016USD ($)
Stock issuance costs	$ 2,500

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (3,708,947)	$ (3,388,791)
Adjustment to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization	1,781	2,231
Stock-based compensation	908,433	966,008
Change in fair value of derivative liability	897,895	(442,165)
Amortization of financing costs	10,091	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	52,050	87,522
Accounts payable	(222,334)	(170,910)
Accrued expenses	(594,030)	(66,315)
Deferred rent	174	(701)
Net cash used in operating activities	(2,654,887)	(3,013,121)
Cash flows from financing activities:
Payment of capital lease obligation	(911)	(785)
Proceeds from issuance of common stock, net of issuance costs of $2,500	5,272,750	0
Net cash provided by (used in) financing activities	5,271,839	(785)
Net increase (decrease) in cash and cash equivalents	2,616,952	(3,013,906)
Cash and cash equivalents at beginning of period	66,988	7,948,436
Cash and cash equivalents at end of period	2,683,940	4,934,530
Supplemental schedule of cash flows information:
Cash paid for interest	284	410
Supplemental schedule of non-cash investing and financing activities:
Conversion of notes payable and interest to common stock	$ 2,128,652	$ 0

CONDENSED STATEMENTS OF CASH F8

CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Issuance Costs	$ 2,500	$ 0

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	3 Months Ended
	Mar. 31, 2016
Business Combination, Description [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Arno Therapeutics, Inc. (“Arno” or the “Company”) is developing innovative drug candidates intended to treat patients with cancer and other life threatening diseases. The Company was incorporated in Delaware in March 2000, at which time its name was Laurier International, Inc. (“Laurier”). Pursuant to an Agreement and Plan of Merger dated March 6, 2008 (as amended, the “Merger Agreement”), by and among the Company, Arno Therapeutics, Inc., a Delaware corporation formed on August 1, 2005 (“Old Arno”), and Laurier Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Laurier Acquisition”), on June 3, 2008, Laurier Acquisition merged with and into Old Arno, with Old Arno remaining as the surviving corporation and a wholly-owned subsidiary of Laurier. Immediately following this merger, Old Arno merged with and into Laurier and Laurier’s name was changed to Arno Therapeutics, Inc. These two merger transactions are hereinafter collectively referred to as the “Merger.” Immediately following the Merger, the former stockholders of Old Arno collectively held 95

BASIS OF PRESENTATION AND SUMMA

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company has not yet generated any revenue from the sale of products and, through March 31, 2016, its efforts have been principally devoted to developing its licensed technologies and raising capital. The Company has experienced negative cash flows from operating activities since its inception and has an accumulated deficit of approximately $ 97.0 The accompanying unaudited Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q adopted under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of Arno’s management, the accompanying Condensed Financial Statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. The interim results for the periods ended March 31, 2016 are not necessarily indicative of results for the full 2016 fiscal year or any other future interim periods. These unaudited Condensed Financial Statements have been prepared by management and should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission. The preparation of financial statements in conformity with generally accepted accounting principles requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees and consultants, and estimates of the probability in the fair value of derivative liabilities. Actual results could differ from those estimates. Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the study and the invoices received from its external service providers. The Company adjusts its accruals when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development expense. The Company accounts for the warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 8) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error. In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Financial Instruments” (“ASU 2016-01”). Equity investments not accounted for under the equity method of accounting will be measured at fair value, with changes in fair value recognized in current earnings. ASU 2016-01 becomes effective for fiscal years beginning after December 15, 2017. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this standard will have a material impact on its financial statements, results of operations or related financial statement disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Leasees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. ASU 2016-02 becomes effective for the Company on January 1, 2019, and early adoption is permitted upon issuance. The Company is evaluating the potential impact of adopting this standard on its financial statements. In March 2016, the FASB issued two updates to Derivatives and Hedging (Topic 815). Accounting Standards Update No. 2016-05, “Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships” (“ASU 2016-05”). ASU 2016-05 clarifies that a change in the counterparty to a derivative instrument that has been designated as a hedging instrument does not, on its own, require dedesignation of that hedge accounting relationship provided that all other hedge accounting criteria continue to be met. Accounting Standards Update No. 2016-06, “Contingent Put and Call Options in Debt Instruments” (“ASU 2016-06”). ASU 2016-06 clarifies that an entity is required to assess the embedded call or put option solely in accordance with a specific four-step decision sequence and are not also required to assess whether the contingency for exercising the option is indexed to interest rate or credit risk. ASU 2016-05 and ASU 2016-06 will take effect for public companies in fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company does not believe the requirements of these updates will have a material effect in the presentation of its financial statements. In March 2016, the FASB issued an update to Compensation- Stock Compensation (Topic 718). Accounting Standards Update No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 identifies areas for simplification involving several aspects of accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. ASU 2016-09 is effective for reporting periods beginning after December 31, 2016. Early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements.

LIQUIDITY AND CAPITAL RESOURCES

LIQUIDITY AND CAPITAL RESOURCES	3 Months Ended
	Mar. 31, 2016
Working Capital Information [Abstract]
LIQUIDITY AND CAPITAL RESOURCES	3. LIQUIDITY AND CAPITAL RESOURCES Cash resources as of March 31, 2016 were approximately $ 2.7 0.1 The long-term success of the Company depends on its ability to develop new products to the point of regulatory approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these developmental efforts. Management plans to raise additional capital either by selling shares of its stock or other securities, issuing additional indebtedness or by licensing the rights to one or more of its product candidates to finance the continued operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s product candidates, acquire rights to additional product candidates and for other working capital purposes. While the Company will extend its best efforts to raise additional capital to fund all operations through June 2016 and beyond, management can provide no assurances that the Company will be successful in raising sufficient funds. If the Company is not successful, it may be required to discontinue its operations. In addition, to the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable to the Company. Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments that might result from the in ability of the Company to continue as a going concern.

BASIC AND DILUTED INCOME_(LOSS)

BASIC AND DILUTED INCOME/(LOSS) PER SHARE	3 Months Ended
	Mar. 31, 2016
Earnings Per Share, Basic and Diluted [Abstract]
BASIC AND DILUTED INCOME/(LOSS) PER SHARE	4. BASIC AND DILUTED INCOME/(LOSS) PER SHARE Basic net loss per share is calculated by dividing the loss available to common shareholders by weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated similarly to basic loss per share except that the denominator is based on the weighted-average number of shares of common stock and other dilutive securities outstanding during the period. The potential dilutive shares of common stock resulting from the assumed exercise of stock options and warrants are determined under the treasury stock method. Three Months Ended March 31, 2016 2015 Warrants to purchase common stock 4,455,231 4,455,231 Options to purchase common stock 162,047 - Total potentially dilutive securities 4,617,278 4,455,231 For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net loss per share as their effect is anti-dilutive. In addition to the potentially dilutive securities, the aggregate number of common equivalent shares (related to options and warrants) that have been excluded from the computations of diluted loss per common share at March 31, 2016 and 2015 were 49,564,330 31,740,566

INTANGIBLE ASSETS AND INTELLECT

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	5. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY License Agreements Onapristone License Agreement The Company’s rights to onapristone are governed by a license agreement with Invivis Pharmaceuticals, Inc. (“Invivis”), dated February 13, 2012. Under this agreement, the Company holds an exclusive, royalty-bearing license for the rights to commercialize onapristone for all therapeutic uses. The license agreement provides the Company with worldwide rights to develop and commercialize onapristone with the exception of the commercialization rights in France; provided that the Company has an option to acquire French commercial rights from Invivis upon notice to Invivis together with additional consideration. The Company made a one-time cash payment of $ 500,000 15.1 150,000 100,000 350,000 70,833 50,000 Under the license agreement with Invivis, the Company also agreed to indemnify and hold Invivis and its affiliates harmless from any and all claims arising out of or in connection with the production, manufacture, sale, use, lease, consumption or advertisement of onapristone, provided, however, that the Company shall have no obligation to indemnify Invivis for claims that (a) any patent rights infringe third party intellectual property, (b) arise out of the gross negligence or willful misconduct of Invivis, or (c) result from a breach of any representation, warranty confidentiality obligation of Invivis under the license agreement. The license agreement will terminate upon the later of (i) the last to expire valid claim contained in the patent rights, and (ii) February 13, 2032 90 90 University of Minnesota License In February 2014, we entered into an Exclusive Patent License Agreement with the Regents of the University of Minnesota, or “UM”, pursuant to which we were granted an exclusive, worldwide, royalty-bearing license for the rights to develop and commercialize technology embodied by certain patent applications relating to a gene expression signature derived from archived breast cancer tissue samples. We plan to develop and commercialize this technology as part of our companion diagnostic development program as a tool to identify progesterone-stimulated pathway activation, which in turn may identify patients who would be more likely to benefit from treatment with onapristone. The license agreement requires us to use commercially reasonable efforts to commercialize the licensed technology as soon as practicable, and includes several performance milestones relating to the development and commercialization of the technology to be achieved by us at specified dates. Under the terms of the agreement, we made a small one-time cash payment and reimbursed UM for past patent expenses it has incurred. The agreement also provides that we will pay royalties to UM on net sales of “Licensed Products” (as defined in the agreement) at a rate in the low-single digits, which royalty obligation terminates on a licensed product-by-licensed product and country-by-country basis upon the first date when there is no longer a valid claim under a licensed patent or patent application covering such licensed product in the country where the licensed product is made or sold. The term of the license agreement continues until the last date on which there is any active licensed patent or pending patent application. UM may terminate the agreement earlier upon a breach by us of one or more of our obligations that remains uncured for a period specified in the agreement. UM may also terminate the agreement if we voluntarily file for bankruptcy or similar proceeding, or if a petition for an involuntary bankruptcy proceeding is filed and is not released for 60 days. The agreement may be immediately terminated upon notice to us if we commence or maintain a proceeding in which we assert that the licensed patents are invalid or unenforceable. We may terminate the agreement at any time and for any reason upon 90 days’ written notice. The license agreement further provides that we will indemnify and hold UM and its affiliates harmless from any and all suits, actions, claims, liabilities, demands, damages, losses or expenses relating to our exercise of its rights under the agreement, including our right to commercialize the licensed technology. UM is required to indemnify us with respect to claims relating to or resulting from its breach of the agreement. AR-12 and AR-42 License Agreements The Company’s rights to both AR-12 and AR-42 are governed by separate license agreements with The Ohio State University Research Foundation (“Ohio State”) entered into in January 2008. Pursuant to each of these agreements, Ohio State granted the Company exclusive, worldwide, royalty-bearing licenses to commercialize certain patent applications, know-how and improvements relating to AR-12 and AR-42 for all therapeutic uses. Under our license agreement for AR-12, we have exclusive, worldwide rights to seven issued U.S. patent and three pending U.S. patent applications that relate to AR-12, AR-12 analogs, and particular uses of AR-12 according to our business plan. On July 9, 2015, the Company and The Ohio State Innovation Foundation (formerly, The Ohio State Research Foundation) (“Ohio State”) entered into an amendment, dated effective as of May 15, 2015 (the “Amendment”), to the parties’ License Agreement dated January 3, 2008 (the “AR-12 License”), pursuant to which the Company was granted an exclusive license to certain patents and other technology relating to its AR-12 product candidate. The purpose of the Amendment was to clarify the scope of AR-12 analogs covered by the license grant in the original AR-12 License. In addition, the Amendment provides the Company with a first option to an exclusive license to patents and other technology relating to compounds related to AR-12 held by Ohio State. The issued patents include composition of matter claims. The issued patents are currently scheduled to expire in 2024. If the pending patent applications issue, the latest of the issued patent or patents would be scheduled to expire in 2034. In 2014, we filed a provisional patent application directed to methods using AR-12 that, if issued, would expire in 2035. In addition, Arno has exclusive rights to a pending US and international patent application directed to AR-12 formulations which, if issued, would expire in 2034. Under our license agreement for AR-42, we have exclusive, worldwide rights to one issued and two pending U.S. patent applications that relate to AR-42 and particular uses of AR-42 according to our business plan. If one of the pending patent applications issues, the issued patent or patents would be scheduled to expire in 2024. If the other pending patent application issues, it would be scheduled to expire in 2034. In 2008, pursuant to our license agreements for AR-12 and AR-42, we made one-time cash payments to Ohio State in the aggregate amount of $ 450,000 6.1 5.0 5.1 4.0 The license agreements with Ohio State further provide that we will indemnify Ohio State from any and all claims arising out of the death of or injury to any person or persons or out of any damage to property, or resulting from the production, manufacture, sale, use, lease, consumption or advertisement of either AR-12 or AR-42, except to the extent that any such claim arises out of the gross negligence or willful misconduct of Ohio State. The license agreements for AR-12 and AR-42, respectively, expire on the later of (i) the expiration of the last valid claim contained in any licensed patent and (ii) 20 90 90

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	3 Months Ended
	Mar. 31, 2016
Convertible Notes Payable [Abstract]
CONVERTIBLE NOTES PAYABLE	6. CONVERTIBLE NOTES PAYABLE On October 21, 2015 6 2,100,000 3,500,000 2,100,000 12,528 On January 12, 2016, in connection with the Stock Purchase Agreement (See note 8) the 6 2,100,000 28,652 6,081,858 0.35 10,091

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	7. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company defines fair value as the amount at which an asset (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The fair value estimates presented in the table below are based on information available to the Company as of March 31, 2016. The accounting standard regarding fair value measurements discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. The Company has determined the fair value of certain liabilities using the market approach. Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs March 31, 2016 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 2,075,631 $ - $ - $ 2,075,631 Warrant liability - 2012 placement agent 8,513 - - 8,513 Warrant liability - 2013 Series D 3,559,908 - - 3,559,908 Warrant liability - 2013 placement agent 4,530 - - 4,530 Total $ 5,648,582 $ - $ - $ 5,648,582 The following table presents the Company’s fair value hierarchy for these liabilities measured at fair value on a recurring basis as of December 31, 2015: Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs December 31, 2015 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 1,753,969 $ - $ - $ 1,753,969 Warrant liability - 2012 placement agent 7,661 - - 7,661 Warrant liability - 2013 Series D 2,985,512 - - 2,985,512 Warrant liability - 2013 placement agent 3,545 - - 3,545 Total $ 4,750,687 $ - $ - $ 4,750,687 Fair Value Measurement Using Significant Unobservable Inputs (Level 3) Total 2013 2012 Warrant 2013 2013 Placement 2012 2012 Placement 2010 Liability Series E Series D Agent Series B Series A Agent Class B Balance at January 1, 2015 $ 6,671,524 $ 25,737 $ 3,011,249 $ 18,907 $ 12,381 $ 3,507,938 $ 67,246 $ 28,066 Total gains or losses: Unrealized appreciation/(depreciation) (1,920,837) (25,737) (25,737) (15,362) (12,381) (1,753,969) (59,585) (28,066) Balance at December 31, 2015 $ 4,750,687 $ - $ 2,985,512 $ 3,545 $ - $ 1,753,969 $ 7,661 $ - Total gains or losses: Unrealized appreciation/(depreciation) 897,895 574,396 985 321,662 852 Balance at March 31, 2016 $ 5,648,582 $ - $ 3,559,908 $ 4,530 $ - $ 2,075,631 $ 8,513 $ - Value per Warrant $ 0.133 $ - $ 0.148 $ 0.069 $ - $ 0.114 $ 0.030 $ -

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2016
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	8. STOCKHOLDERS’ EQUITY Common Stock As of March 31, 2016, the Company had 41,562,613 54,181,608 On January 12, 2016, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with certain purchasers identified therein (the “Purchasers”) pursuant to which the Company agreed to sell, and the Purchasers agreed to purchase, an aggregate of 21,153,997 0.35 7,400,000 2,100,000 6,081,858 6 2,100,000 28,652 Warrants In accordance with the 2010 sale and issuance of Series A preferred stock, the Company issued two-and-one-half-year “Class A” warrants to purchase an aggregate of 152,740 8.00 five 801,885 9.20 3.55 0.0 152,740 801,885 Pursuant to the 2012 Purchase Agreement for the sale and issuance of 8 five 6,190,500 4.00 6,190,500 2.40 12 2.40 10,317,464 1.36 18,207,273 2.1 1.8 6,190,500 In connection with the sale of the Debentures and 2012 Warrants, the Company engaged Maxim Group LLC, or Maxim, to serve as placement agent. In consideration for its services, the Company paid Maxim a placement fee of $ 1,035,000 7,500 five 283,750 2.64 0.0 Under the terms of the 2013 Purchase Agreement for the issuance and sale of common stock, each Purchaser received Series D and Series E Warrants and had the option to elect to receive a Series C Warrant in lieu of a Share in connection with each Unit it purchased. The Series C Warrants have a five 0.01 five 4.00 2.40 4.00 2.14 12,868,585 24,053,398 3.6 3.0 12,868,585 The 2013 Warrants are required to be exercised for cash, provided that if during the term of the Warrants there is not an effective registration statement under the Securities Act covering the resale of the shares issuable upon exercise of the Warrants, then the Warrants may be exercised on a cashless (net exercise) basis. Grant Date Warrants Issued Exercise Weighted Average Expiration Exercised Warrants 11/26/2012 15,569,787 $ 1.36 $ 1.36 11/26/2017 - 15,569,787 11/26/2012 261,250 $ 2.64 $ 2.64 11/26/2017 - 261,250 12/18/2012 2,637,486 $ 1.36 $ 1.36 12/18/2017 - 2,637,486 12/18/2012 22,500 $ 2.64 $ 2.64 12/18/2017 - 22,500 10/29/2013 4,455,231 $ 0.01 $ 0.01 10/29/2018 - 4,455,231 10/29/2013 24,053,398 $ 2.14 $ 2.14 10/29/2018 - 24,053,398 10/29/2013 65,650 $ 2.64 $ 2.64 10/29/2018 - 65,650 47,065,302 $ 1.64 - 47,065,302

STOCK OPTION PLAN

STOCK OPTION PLAN	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK OPTION PLAN	9. STOCK OPTION PLAN The Company’s 2005 Stock Option Plan (the “2005 Plan”) was originally adopted by the Board of Directors of Old Arno in August 2005, and was assumed by the Company on June 3, 2008 in connection with the Merger. After giving effect to the Merger, there were initially 373,831 875,000 945,276 11,155,295 The 2005 Plan is administered by the Board, or a committee appointed by the Board, which determines recipients and types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The term of stock options granted under the 2005 Plan cannot exceed 10 The 2005 Plan expired on March 31, 2016 and no further awards will be made pursuant to this plan. On March 14, 2016, the Board of the Company adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan replaces the Company’s 2005 Plan. Incentives under the 2016 Plan may be granted in any one or a combination of the following forms: (a) incentive stock options and non-statutory stock options, (b) stock appreciation rights, (c) stock awards, (d) restricted stock and (e) performance shares. The stock to be awarded or optioned under the 2016 Plan will consist of authorized but unissued or reacquired shares of common stock. The maximum aggregate number of shares of common stock reserved and available for awards under the 2016 Plan is 9,000,000 shares; provided, that all shares of stock reserved and available under the 2016 Plan will constitute the maximum aggregate number of shares of stock that may be issued through incentive stock options. Any employee, director, or consultant may participate in the 2016 Plan; provided, however, that only employees are eligible to receive incentive stock options. Additionally, the Company may grant certain performance-based awards to “covered employees” in compliance with Section 162(m) of the Internal Revenue Code. These covered employees include our executive officers. No person may be granted options, stock appreciation rights, restricted stock awards, restricted stock units or performance awards under the 2016 Plan for more than 2,000,000 The term of stock options granted under the 2016 Plan cannot exceed 10 As of March 31, 2016, there are 9,000,000 Three Months Ended March 31, 2016 2015 Options granted 88,648 - Three Months Ended March 31, 2016 2015 Expected volatility 82 % N/A Expected term 6 years N/A Dividend yield 0.0 % N/A Risk- free interest rate 1.55 % N/A Stock price $ 0.30 N/A Forfeiture rate 0.0 % N/A A summary of the status of the options issued under the Company’s Plans at March 31, 2016, and information with respect to the changes in options outstanding, is as follows: Weighted- Aggregate Number of Average Intrinsic Shares Exercise Price Value Options outstanding at December 31, 2015 7,027,658 $ 2.57 $ 1,218 Granted 88,648 0.30 7,092 Exercised - - - Cancelled - - - Options outstanding at March 31, 2016 7,116,306 $ 2.55 $ 8,310 Options vested and expected to vest at March 31, 2016 7,116,306 $ 2.55 $ 8,310 Exercisable at March 31, 2016 5,482,305 $ 2.65 $ 501 Shares available for grant under the 2016 Plan 9,000,000 Outstanding Exercisable Weighted- Average Weighted- Remaining Average Weighted- Number of Contractual Exercise Number Average Exercise Price Shares Life (Years) Price of Shares Exercise Price $ 0.30 88,648 9.78 $ 0.30 4,924 $ 0.30 $ 0.36 48,399 9.59 $ 0.36 5,377 $ 0.36 $ 0.37 25,000 9.69 $ 0.37 - $ 0.37 $ 0.85 136,785 8.59 $ 0.85 60,793 $ 0.85 $ 1.30 100,000 8.52 $ 1.30 40,625 $ 1.30 $ 2.23 97,757 - $ 2.23 97,757 $ 2.23 $ 2.40 5,097,075 6.96 $ 2.40 4,119,154 $ 2.40 $ 2.90 1,420,259 7.82 $ 2.90 1,051,292 $ 2.90 $ 8.00 65,000 4.32 $ 8.00 65,000 $ 8.00 $ 19.38 37,383 2.03 $ 19.38 37,383 $ 19.38 Total 7,116,306 7.10 $ 2.55 5,482,305 $ 2.65 Three Months Ended March 31, 2016 2015 Research and development $ 171,821 $ 269,803 General and administrative 736,612 696,205 Total $ 908,433 $ 966,008 The grant date fair value of options vested under the Plan was approximately $ 911,149 1,680,837 At March 31, 2016, total unrecognized estimated compensation cost related to stock options granted prior to that date was approximately $ 2,681,012 2.8 Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model and is expensed as the underlying options vest. The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	10. SUBSEQUENT EVENTS On April 7, 2016 the Company’s Board of Directors made a strategic determination to focus the Company’s resources on its prostate cancer program and to close the Company’s ongoing Phase II clinical trial of onapristone in patients with recurrent or metastatic endometrioid cancer. This decision was not based on any safety or lack of efficacy signal and the Company will continue to provide onapristone to all patients currently enrolled in this trial on a compassionate use basis.

BASIS OF PRESENTATION AND SUM19

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the study and the invoices received from its external service providers. The Company adjusts its accruals when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
Warrant Liability	Warrant Liability The Company accounts for the warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 8) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.
Recently Issued Accounting Pronouncements	In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Financial Instruments” (“ASU 2016-01”). Equity investments not accounted for under the equity method of accounting will be measured at fair value, with changes in fair value recognized in current earnings. ASU 2016-01 becomes effective for fiscal years beginning after December 15, 2017. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this standard will have a material impact on its financial statements, results of operations or related financial statement disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Leasees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. ASU 2016-02 becomes effective for the Company on January 1, 2019, and early adoption is permitted upon issuance. The Company is evaluating the potential impact of adopting this standard on its financial statements. In March 2016, the FASB issued two updates to Derivatives and Hedging (Topic 815). Accounting Standards Update No. 2016-05, “Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships” (“ASU 2016-05”). ASU 2016-05 clarifies that a change in the counterparty to a derivative instrument that has been designated as a hedging instrument does not, on its own, require dedesignation of that hedge accounting relationship provided that all other hedge accounting criteria continue to be met. Accounting Standards Update No. 2016-06, “Contingent Put and Call Options in Debt Instruments” (“ASU 2016-06”). ASU 2016-06 clarifies that an entity is required to assess the embedded call or put option solely in accordance with a specific four-step decision sequence and are not also required to assess whether the contingency for exercising the option is indexed to interest rate or credit risk. ASU 2016-05 and ASU 2016-06 will take effect for public companies in fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company does not believe the requirements of these updates will have a material effect in the presentation of its financial statements. In March 2016, the FASB issued an update to Compensation- Stock Compensation (Topic 718). Accounting Standards Update No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 identifies areas for simplification involving several aspects of accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. ASU 2016-09 is effective for reporting periods beginning after December 31, 2016. Early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements.

BASIC AND DILUTED INCOME_(LOS20

BASIC AND DILUTED INCOME/(LOSS) PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share, Basic and Diluted [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	As of March 31, 2016 and 2015, potentially dilutive securities include: Three Months Ended March 31, 2016 2015 Warrants to purchase common stock 4,455,231 4,455,231 Options to purchase common stock 162,047 - Total potentially dilutive securities 4,617,278 4,455,231

FAIR VALUE OF FINANCIAL INSTR21

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s fair value hierarchy for these liabilities measured at fair value on a recurring basis as of March 31, 2016: Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs March 31, 2016 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 2,075,631 $ - $ - $ 2,075,631 Warrant liability - 2012 placement agent 8,513 - - 8,513 Warrant liability - 2013 Series D 3,559,908 - - 3,559,908 Warrant liability - 2013 placement agent 4,530 - - 4,530 Total $ 5,648,582 $ - $ - $ 5,648,582 The following table presents the Company’s fair value hierarchy for these liabilities measured at fair value on a recurring basis as of December 31, 2015: Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs December 31, 2015 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 1,753,969 $ - $ - $ 1,753,969 Warrant liability - 2012 placement agent 7,661 - - 7,661 Warrant liability - 2013 Series D 2,985,512 - - 2,985,512 Warrant liability - 2013 placement agent 3,545 - - 3,545 Total $ 4,750,687 $ - $ - $ 4,750,687
Summary of Changes in Fair Value of Liabilities	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held at March 31, 2016: Fair Value Measurement Using Significant Unobservable Inputs (Level 3) Total 2013 2012 Warrant 2013 2013 Placement 2012 2012 Placement 2010 Liability Series E Series D Agent Series B Series A Agent Class B Balance at January 1, 2015 $ 6,671,524 $ 25,737 $ 3,011,249 $ 18,907 $ 12,381 $ 3,507,938 $ 67,246 $ 28,066 Total gains or losses: Unrealized appreciation/(depreciation) (1,920,837) (25,737) (25,737) (15,362) (12,381) (1,753,969) (59,585) (28,066) Balance at December 31, 2015 $ 4,750,687 $ - $ 2,985,512 $ 3,545 $ - $ 1,753,969 $ 7,661 $ - Total gains or losses: Unrealized appreciation/(depreciation) 897,895 574,396 985 321,662 852 Balance at March 31, 2016 $ 5,648,582 $ - $ 3,559,908 $ 4,530 $ - $ 2,075,631 $ 8,513 $ - Value per Warrant $ 0.133 $ - $ 0.148 $ 0.069 $ - $ 0.114 $ 0.030 $ -

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2016
Stockholders Equity Note [Abstract]
Summary of All Outstanding Warrants to Purchase Shares of Common Stock	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of March 31, 2016: Grant Date Warrants Issued Exercise Weighted Average Expiration Exercised Warrants 11/26/2012 15,569,787 $ 1.36 $ 1.36 11/26/2017 - 15,569,787 11/26/2012 261,250 $ 2.64 $ 2.64 11/26/2017 - 261,250 12/18/2012 2,637,486 $ 1.36 $ 1.36 12/18/2017 - 2,637,486 12/18/2012 22,500 $ 2.64 $ 2.64 12/18/2017 - 22,500 10/29/2013 4,455,231 $ 0.01 $ 0.01 10/29/2018 - 4,455,231 10/29/2013 24,053,398 $ 2.14 $ 2.14 10/29/2018 - 24,053,398 10/29/2013 65,650 $ 2.64 $ 2.64 10/29/2018 - 65,650 47,065,302 $ 1.64 - 47,065,302

STOCK OPTION PLAN (Tables)

STOCK OPTION PLAN (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of Share-based Compensation, Activity	The Company issued the following stock options during the three month periods ended March 31, 2016 and 2015, respectively: Three Months Ended March 31, 2016 2015 Options granted 88,648 -
Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model	The Company estimated the fair value of each option award granted using the Black-Scholes option-pricing model. The following assumptions were used for the three months ended March 31, 2016 as no options were granted in the three months ended March 31, 2015: Three Months Ended March 31, 2016 2015 Expected volatility 82 % N/A Expected term 6 years N/A Dividend yield 0.0 % N/A Risk- free interest rate 1.55 % N/A Stock price $ 0.30 N/A Forfeiture rate 0.0 % N/A
Summary of Status of Options Issued And Changes in Options Outstanding	A summary of the status of the options issued under the Company’s Plans at March 31, 2016, and information with respect to the changes in options outstanding, is as follows: Weighted- Aggregate Number of Average Intrinsic Shares Exercise Price Value Options outstanding at December 31, 2015 7,027,658 $ 2.57 $ 1,218 Granted 88,648 0.30 7,092 Exercised - - - Cancelled - - - Options outstanding at March 31, 2016 7,116,306 $ 2.55 $ 8,310 Options vested and expected to vest at March 31, 2016 7,116,306 $ 2.55 $ 8,310 Exercisable at March 31, 2016 5,482,305 $ 2.65 $ 501 Shares available for grant under the 2016 Plan 9,000,000
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at March 31, 2016: Outstanding Exercisable Weighted- Average Weighted- Remaining Average Weighted- Number of Contractual Exercise Number Average Exercise Price Shares Life (Years) Price of Shares Exercise Price $ 0.30 88,648 9.78 $ 0.30 4,924 $ 0.30 $ 0.36 48,399 9.59 $ 0.36 5,377 $ 0.36 $ 0.37 25,000 9.69 $ 0.37 - $ 0.37 $ 0.85 136,785 8.59 $ 0.85 60,793 $ 0.85 $ 1.30 100,000 8.52 $ 1.30 40,625 $ 1.30 $ 2.23 97,757 - $ 2.23 97,757 $ 2.23 $ 2.40 5,097,075 6.96 $ 2.40 4,119,154 $ 2.40 $ 2.90 1,420,259 7.82 $ 2.90 1,051,292 $ 2.90 $ 8.00 65,000 4.32 $ 8.00 65,000 $ 8.00 $ 19.38 37,383 2.03 $ 19.38 37,383 $ 19.38 Total 7,116,306 7.10 $ 2.55 5,482,305 $ 2.65
Stock-Based Compensation Costs	Stock-based compensation costs under the Plan for the three month periods ended March 31, 2016 and 2015 are as follows: Three Months Ended March 31, 2016 2015 Research and development $ 171,821 $ 269,803 General and administrative 736,612 696,205 Total $ 908,433 $ 966,008

Description of Business - Addit

Description of Business - Additional Information (Detail)	Mar. 31, 2016
Organization and Nature of Operations [Line Items]
Percentage of outstanding common stock collectively held by former stockholders of Old Arno	95.00%

Basis of Presentation and Sum25

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit	$ (97,003,900)	$ (93,294,953)

Liquidity and Capital Resourc26

Liquidity and Capital Resources - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Working Capital Detail [Line Items]
Cash and cash equivalents	$ 2,683,940	$ 66,988	$ 4,934,530	$ 7,948,436

Potentially Dilutive Securities

Potentially Dilutive Securities (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	4,617,278	4,455,231
Warrants to purchase common stock
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	4,455,231	4,455,231
Options to purchase common stock
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	162,047	0

Basic and Diluted Income_(Los28

Basic and Diluted Income/(Loss) Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	49,564,330	31,740,566

Intangible Assets and Intelle29

Intangible Assets and Intellectual Property - Additional Information (Detail) - USD ($)	Apr. 01, 2014	Feb. 13, 2012	Jul. 31, 2015	Feb. 28, 2014	Jan. 31, 2014	Oct. 31, 2013	Dec. 31, 2008
Finite-Lived Intangible Assets [Line Items]
Services agreement monthly payment	$ 50,000	$ 70,833
University of Minnesota
Finite-Lived Intangible Assets [Line Items]
Written notice period for termination of license agreement if breach is not cured				60 days
Prior written notice period for termination of license agreement by the company for any reason				90 days
Onapristone License Agreement
Finite-Lived Intangible Assets [Line Items]
Written notice period for termination of license agreement if breach is not cured		90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement		$ 500,000			$ 100,000	$ 150,000
Aggregate potential milestone payments		$ 15,100,000
License agreement termination date		Feb. 13, 2032
Prior written notice period for termination of license agreement by the company for any reason		90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc | Next Milestone Payment
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement			$ 350,000
AR-12 and AR-42 License Agreements | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement							$ 450,000
Written notice period for termination of license agreement if breach is not cured							90 days
Prior written notice period for termination of license agreement by the company for any reason							90 days
License agreement expiration date							20 years
AR-12 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments							$ 6,100,000
Potential milestone payments, due after market approval							5,000,000
AR-42 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments							5,100,000
Potential milestone payments, due after market approval							$ 4,000,000

Convertible Notes Payable - (Ad

Convertible Notes Payable - (Additional Information) (Detail) - USD ($)	Jan. 12, 2016	Oct. 21, 2016	Oct. 21, 2015	Dec. 31, 2015	Dec. 31, 2012
Convertible Long Term Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.00%				8.00%
Debt Conversion, Converted Instrument, Amount	$ 2,100,000
Unamortized Debt Issuance Expense				$ 10,091
Convertible Notes Payable
Convertible Long Term Notes Payable [Line Items]
Potential Additional Equity Financing			$ 3,500,000
Debt Issuance Cost			12,528
Convertible Note Payable, Face Amount			$ 2,100,000
Debt Instrument, Interest Rate, Stated Percentage			6.00%
Debt Conversion, Converted Instrument, Amount			$ 2,100,000
Debt Instrument, Maturity Date		Oct. 21, 2016
Stock Purchase Agreement | Convertible Notes Payable
Convertible Long Term Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Conversion, Converted Instrument, Amount	$ 2,100,000
Debt Conversion, Converted Instrument, Shares Issued	6,081,858
Shares Issued, Price Per Share	$ 0.35
Unamortized Debt Issuance Expense	$ 10,091
Stock Purchase Agreement | Convertible Notes, Accrued Interest
Convertible Long Term Notes Payable [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 28,652

Fair Value Hierarchy for Liabil

Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Liabilities
Derivative Liabilities Noncurrent	$ 5,648,582	$ 4,750,687
Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	5,648,582	4,750,687
Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	2,075,631	1,753,969
Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	8,513	7,661
Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	3,559,908	2,985,512
Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	4,530	3,545
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	5,648,582	4,750,687
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	2,075,631	1,753,969
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	8,513	7,661
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	3,559,908	2,985,512
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	$ 4,530	$ 3,545

Summary of Changes in Fair Valu

Summary of Changes in Fair Value of Liabilities (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
2013 Series E
Warrant Liability
Balance	$ 0	$ 25,737
Total gains or losses:
Unrealized appreciation/(depreciation)		(25,737)
Balance	$ 0	0
Value per Warrant	$ 0
2013 Series D
Warrant Liability
Balance	$ 2,985,512	3,011,249
Total gains or losses:
Unrealized appreciation/(depreciation)	574,396	(25,737)
Balance	$ 3,559,908	2,985,512
Value per Warrant	$ 0.148
2013 Placement Agent
Warrant Liability
Balance	$ 3,545	18,907
Total gains or losses:
Unrealized appreciation/(depreciation)	985	(15,362)
Balance	$ 4,530	3,545
Value per Warrant	$ 0.069
2012 Series B
Warrant Liability
Balance	$ 0	12,381
Total gains or losses:
Unrealized appreciation/(depreciation)		(12,381)
Balance	$ 0	0
Value per Warrant	$ 0
2012 Series A
Warrant Liability
Balance	$ 1,753,969	3,507,938
Total gains or losses:
Unrealized appreciation/(depreciation)	321,662	(1,753,969)
Balance	$ 2,075,631	1,753,969
Value per Warrant	$ 0.114
2012 Placement Agent
Warrant Liability
Balance	$ 7,661	67,246
Total gains or losses:
Unrealized appreciation/(depreciation)	852	(59,585)
Balance	$ 8,513	7,661
Value per Warrant	$ 0.030
2010 Class B
Warrant Liability
Balance	$ 0	28,066
Total gains or losses:
Unrealized appreciation/(depreciation)		(28,066)
Balance	$ 0	0
Value per Warrant	$ 0
Warrant
Warrant Liability
Balance	$ 4,750,687	6,671,524
Total gains or losses:
Unrealized appreciation/(depreciation)	897,895	(1,920,837)
Balance	$ 5,648,582	$ 4,750,687
Value per Warrant	$ 0.133

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Jan. 12, 2016	Sep. 30, 2015	Jan. 31, 2015	Mar. 31, 2016	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2015
Stockholders Equity Note [Line Items]
Common stock, shares issued				41,562,613				20,408,616
Common stock, shares outstanding				41,562,613				20,408,616
Derivative liabilities				$ 5,648,582				$ 4,750,687
Debt Instrument, Interest Rate, Stated Percentage	6.00%					8.00%
Potential Additional Equity Financing						$ 12,000,000
Shares Of Common Stock Reserved For Issuance Upon The Exercise Of Outstanding Options And Warrants				54,181,608
Stock Issued During Period Shares New Issues	21,153,997
Debt Conversion, Converted Instrument, Amount	$ 2,100,000
Stock Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Proceeds from the issuance of stock, warrants, or units	$ 7,400,000
Shares Issued, Price Per Share	$ 0.35
Debt Conversion, Converted Instrument, Amount	$ 2,100,000
Debt Conversion, Converted Instrument, Shares Issued	6,081,858
Maxim Group Llc
Stockholders Equity Note [Line Items]
Common stock, shares issued						7,500
Number of securities called by warrants						283,750
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 2.64
Warrant Term						5 years
Derivative liabilities				$ 0				0
Placement Fee Paid						$ 1,035,000
Convertible Notes, Accrued Interest [Member]
Stockholders Equity Note [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 28,652
Class A Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants							152,740
Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights							$ 8
Number Of Warrants Expired Unexercised					152,740
Class B Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants							801,885
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 3.55
Warrant Term							5 years
Derivative liabilities								0
Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights							$ 9.20
Number Of Warrants Expired Unexercised		801,885
Series A Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants				18,207,273	10,317,464	6,190,500
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.36	$ 2.40	$ 4
Warrant Term						5 years
Series B Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants						6,190,500
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 2.40
Number Of Warrants Expired Unexercised			6,190,500
Future Issuance of Equity and Debt Security Term						18 months
Series D Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 4
Warrant Term					5 years
Derivative liabilities				$ 3,600,000				3,000,000
Series E Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2.40
Number Of Warrants Expired Unexercised			12,868,585
Securities Purchase and Registration Rights Agreement | Series C Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.01
Warrant Term					5 years
Series A and B Warrants
Stockholders Equity Note [Line Items]
Derivative liabilities				$ 2,100,000				$ 1,800,000
Maximum | Series D Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants				24,053,398
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.14
Minimum | Series D Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants				12,868,585
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 4

Summary of All Outstanding Warr

Summary of All Outstanding Warrants to Purchase Shares of Common Stock (Detail)	3 Months Ended
	Mar. 31, 2016$ / shares$ / Warrantsshares
Warrant 1
Class of Warrant or Right [Line Items]
Grant Date	Nov. 26, 2012
Warrants Issued	15,569,787
Exercise Price | $ / shares	$ 1.36
Weighted Average Exercise Price | $ / Warrants	1.36
Expiration Date	Nov. 26, 2017
Exercised	0
Warrants Outstanding	15,569,787
Warrant 2
Class of Warrant or Right [Line Items]
Grant Date	Nov. 26, 2012
Warrants Issued	261,250
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrants	2.64
Expiration Date	Nov. 26, 2017
Exercised	0
Warrants Outstanding	261,250
Warrant 3
Class of Warrant or Right [Line Items]
Grant Date	Dec. 18, 2012
Warrants Issued	2,637,486
Exercise Price | $ / shares	$ 1.36
Weighted Average Exercise Price | $ / Warrants	1.36
Expiration Date	Dec. 18, 2017
Exercised	0
Warrants Outstanding	2,637,486
Warrant 4
Class of Warrant or Right [Line Items]
Grant Date	Dec. 18, 2012
Warrants Issued	22,500
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrants	2.64
Expiration Date	Dec. 18, 2017
Exercised	0
Warrants Outstanding	22,500
Warrant 5
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	4,455,231
Exercise Price | $ / shares	$ 0.01
Weighted Average Exercise Price | $ / Warrants	0.01
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	4,455,231
Warrant 6
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	24,053,398
Exercise Price | $ / shares	$ 2.14
Weighted Average Exercise Price | $ / Warrants	2.14
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	24,053,398
Warrant 7
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	65,650
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrants	2.64
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	65,650
Total Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants Issued	47,065,302
Weighted Average Exercise Price | $ / Warrants	1.64
Exercised	0
Warrants Outstanding	47,065,302

Stock Option Plan - Additional

Stock Option Plan - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Oct. 07, 2013	Jan. 14, 2013	Apr. 25, 2011	Jun. 03, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted (in years)	7 years 1 month 6 days
Fair value of options vested under 2005 Plan	$ 911,149	$ 1,680,837
Total unrecognized estimated compensation cost related to stock options	$ 2,681,012
Total unrecognized estimated compensation cost related to stock options, recognition period	2 years 9 months 18 days
2005 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance			11,155,295	945,276	875,000	373,831
Term of stock options granted (in years)	10 years
2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted (in years)	10 years
Stock Options Fiscal Twenty Zero Six Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance	9,000,000
Share-based Compensation Arrangement by Share-based Payment Award Maximum Number Of Shares Issuable	2,000,000

Options Granted (Detail)

Options Granted (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted	88,648	0

Assumptions Used in Estimating

Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2016$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Volatility	82.00%
Expected term	6 years
Dividend yield	0.00%
Risk-free interest rate	1.55%
Stock price	$ 0.30
Forfeiture rate	0.00%

Summary of Status of Options Is

Summary of Status of Options Issued and Changes in Options Outstanding (Detail)	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Number of Shares
Ending Balance	7,116,306
Exercisable	5,482,305
Weighted-Average Exercise Price
Ending Balance | $ / shares	$ 2.55
Exercisable | $ / shares	$ 2.65
Stock Option Plan
Number of Shares
Beginning Balance	7,027,658
Options Granted	88,648
Options Exercised	0
Options Cancelled	0
Ending Balance	7,116,306
Options vested and expected to vest	7,116,306
Exercisable	5,482,305
Shares available for grant under the 2016 Plan	9,000,000
Weighted-Average Exercise Price
Beginning Balance | $ / shares	$ 2.57
Options Granted | $ / shares	0.30
Options Exercised | $ / shares	0
Options Cancelled | $ / shares	0
Ending Balance | $ / shares	2.55
Options vested and expected to vest | $ / shares	2.55
Exercisable | $ / shares	$ 2.65
Aggregate Intrinsic Value
Beginning Balance | $	$ 1,218
Options Granted | $	7,092
Options Exercised | $	0
Options Cancelled | $	0
Ending Balance | $	8,310
Options vested and expected | $	8,310
Exercisable | $	$ 501

Summary of Information about St

Summary of Information about Stock Options Outstanding (Detail)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	7,116,306
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 1 month 6 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.55
Options Exercisable, Shares | shares	5,482,305
Options Exercisable, Weighted- Average Exercise Price	$ 2.65
Exercise Price 0.30
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.30
Options Outstanding, Shares | shares	88,648
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 9 months 11 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.30
Options Exercisable, Shares | shares	4,924
Options Exercisable, Weighted- Average Exercise Price	$ 0.30
Exercise Price 0.36
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.36
Options Outstanding, Shares | shares	48,399
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 7 months 2 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.36
Options Exercisable, Shares | shares	5,377
Options Exercisable, Weighted- Average Exercise Price	$ 0.36
Exercise Price 0.37
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.37
Options Outstanding, Shares | shares	25,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 8 months 8 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.37
Options Exercisable, Shares | shares	0
Options Exercisable, Weighted- Average Exercise Price	$ 0.37
Exercise Price 0.85
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.85
Options Outstanding, Shares | shares	136,785
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 7 months 2 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.85
Options Exercisable, Shares | shares	60,793
Options Exercisable, Weighted- Average Exercise Price	$ 0.85
Exercise Price 1.30
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 1.30
Options Outstanding, Shares | shares	100,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 6 months 7 days
Options Outstanding, Weighted-Average Exercise Price	$ 1.30
Options Exercisable, Shares | shares	40,625
Options Exercisable, Weighted- Average Exercise Price	$ 1.30
Exercise Price 2.23
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 2.23
Options Outstanding, Shares | shares	97,757
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	0 years
Options Outstanding, Weighted-Average Exercise Price	$ 2.23
Options Exercisable, Shares | shares	97,757
Options Exercisable, Weighted- Average Exercise Price	$ 2.23
Exercise Price 2.40
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 2.40
Options Outstanding, Shares | shares	5,097,075
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	6 years 11 months 16 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.40
Options Exercisable, Shares | shares	4,119,154
Options Exercisable, Weighted- Average Exercise Price	$ 2.40
Exercise Price 2.90
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 2.90
Options Outstanding, Shares | shares	1,420,259
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 9 months 25 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.90
Options Exercisable, Shares | shares	1,051,292
Options Exercisable, Weighted- Average Exercise Price	$ 2.90
Exercise price 8.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 8
Options Outstanding, Shares | shares	65,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	4 years 3 months 25 days
Options Outstanding, Weighted-Average Exercise Price	$ 8
Options Exercisable, Shares | shares	65,000
Options Exercisable, Weighted- Average Exercise Price	$ 8
Exercise price 19.38
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 19.38
Options Outstanding, Shares | shares	37,383
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	2 years 11 days
Options Outstanding, Weighted-Average Exercise Price	$ 19.38
Options Exercisable, Shares | shares	37,383
Options Exercisable, Weighted- Average Exercise Price	$ 19.38

Stock-Based Compensation Costs

Stock-Based Compensation Costs (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 908,433	$ 966,008
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	171,821	269,803
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 736,612	$ 696,205